Huagai Capital

Portfolio Co Investors 2026 for Huagai Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Huagai Capital accounts for 9 tracked companies with verified cap-table data, 9 of which disclose round sizes totalling $1.1B. The median disclosed raise is $100M, and the largest is Shukun Technology at $274M, ahead of Beijing Gene+ Technology ($220M) and JOINN Biologics ($210M).

The names that recur most often on these co-invested cap tables are Huagai Capital (9 companies), Sequoia Capital China (2 companies), Sherpa Healthcare Partners (2 companies), Goldman Sachs (1 company), Primavera Capital Group (1 company), Qiming Venture Partners (1 company). By latest disclosed round, the market skews Series B (4), Series A (2), Other Equity (1), Series D (1).

Best funded Huagai Capital companies

  1. Shukun Technology — $274M (latest: Other Equity)
  2. Beijing Gene+ Technology — $220M (latest: Series D)
  3. JOINN Biologics — $210M (latest: Series B)
  4. EdiGene — $129M (latest: Series B)
  5. Reistone Biopharma — $100M (latest: Series A)
  6. Singlomics — $62M (latest: Series B)
  7. Synaptic Medical — $60M (latest: Series G)
  8. Hyperway Pharm — $54M (latest: Series B)
  9. PAQ Therapeutics — $30M (latest: Series A)

Huagai Capital — related firms and companies (52)

Huagai Capital alternatives · All research reports